文献速递产科母胎医学

母体二甲双胍能否保护发育中的胎儿大脑?

Can maternal metformin protect the developing fetal brain?
PubMed 文献 · Am J Obstet Gynecol · 2025-10-21

该嵌套病例对照研究基于一项随机对照试验的母体样本,比较二甲双胍(1000毫克每日两次)联合胰岛素与单用胰岛素对胎儿神经元来源细胞外囊泡生物标志物的影响。结果显示二甲双胍暴露与Sirtuin-1升高39%相关,其他标志物无显著差异,囊泡与胎儿脑组织Sirtuin-1高度相关。

要点

  • 二甲双胍暴露与胎儿神经元来源细胞外囊泡Sirtuin-1升高39%相关(b=0.331,95%CI 0.023-0.640,P=.039)。
  • 其他生物标志物(肿瘤坏死因子-α和Bcl-2相关X蛋白)未见显著差异。
  • 囊泡与胎儿脑组织Sirtuin-1高度相关(ρ=0.513,95%CI 0.211-0.720,P=.003),支持囊泡生物标志物作为有效替代指标。

核心结论

  • 母体二甲双胍治疗增加胎儿脑Sirtuin-1,该变化通过支持神经元分化和防止线粒体丢失对发育中的胎儿大脑有益。
  • 较低的Sirtuin-1可能促成认知障碍和脑可塑性降低。
  • 临床医生可将此新信息加入孕妇使用二甲双胍的风险获益分析。
  • 需要进一步研究以更好地理解二甲双胍的潜在神经保护作用。

研究设计与样本

  • 对一项随机对照试验的母体样本进行嵌套病例对照研究,该试验比较二甲双胍(1000毫克每日两次)联合胰岛素与单用胰岛素治疗围产期2型糖尿病(每组n=40)或妊娠期糖尿病。
  • 从24至30周采集的母体血清中纯化胎儿神经元来源的细胞外囊泡,定量Sirtuin-1、肿瘤坏死因子-α和Bcl-2相关X蛋白。
  • 在第二组自愿终止妊娠的个体中验证囊泡与胎儿脑组织生物标志物浓度之间的相关性。
  • 采用广义线性模型评估二甲双胍治疗对胎儿神经元标志物的影响。

主要发现

  • 宫内暴露于二甲双胍与胎儿神经元来源细胞外囊泡中Sirtuin-1升高39%相关(b=0.331;95%置信区间,0.023,0.640;P=.039)。
  • 其他生物标志物未见显著差异。
  • 囊泡与匹配的胎儿脑组织中Sirtuin-1高度相关(ρ=0.513;95%置信区间=0.211,0.720;P=.003),支持使用囊泡生物标志物作为有效替代指标。

临床怎么用

  • 临床医生可将此新信息加入孕妇使用二甲双胍的风险获益分析。
  • 需要进一步研究以更好地理解二甲双胍的潜在神经保护作用。

局限性

  • 需要进一步研究以更好地理解二甲双胍的潜在神经保护作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Maternal diabetes is associated with an increased risk of autism spectrum disorder and attention-deficit hyperactivity disorder. Metformin has an emerging role as a neuroprotective agent, both in perinatal preclinical models and in nonobstetric clinical trials. Metformin crosses the placenta and fetal exposure has potential risks and benefits. New techniques allow for isolation of extracellular vesicles that originate from fetal neurons and cross the placenta into maternal blood, providing a window into ongoing neurodevelopment. OBJECTIVE: To determine if maternal treatment with metformin for maternal diabetes had beneficial effects on biomarkers of fetal brain health. STUDY DESIGN: A nested case-control study was performed on maternal samples from a randomized controlled trial of metformin (1000 mg twice daily) + insulin vs insulin only for perinatal type 2 diabetes mellitus (n=40 in each group) or gestational diabetes mellitus. Fetal neuronally derived extracellular vesicles were purified from maternal serum collected at 24 to 30 weeks. Sirtuin-1, tumor necrosis factor-alpha and Bcl-2-associated X protein were quantified. Correlation between vesicle and fetal brain concentrations of biomarkers was validated in a second set of individuals undergoing voluntary pregnancy termination. Generalized linear modeling was performed to evaluate the effect of metformin treatment on fetal neuronal markers. RESULTS: In-utero exposure to metformin was associated with a 39% increase in Sirtuin-1 (b=0·331; 95% confidence interval, 0.023, 0.640; P=.039) in fetal neuronally derived extracellular vesicles. No significant differences were observed in other biomarkers. Sirtuin-1 in vesicles and matched fetal brain tissue were highly correlated (ρ=0·513; 95% confidence interval=0.211, 0.720; P=.003) supporting the use of vesicle biomarkers as a valid proxy measure. CONCLUSION: Maternal metformin treatment increases fetal brain Sirtuin-1, a change that is beneficial for the developing fetal brain through support of neuronal differentiation and prevention of mitochondrial loss. Lower Sirtuin-1 may contribute to cognitive impairments and reduced brain plasticity. Clinicians can add this new information to the risk benefit analysis of metformin use in pregnant women. Further research is needed to better understand the potential neuroprotective role of metformin.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Ibarra C, Fekry B, Ugartemendia L, et al. Can maternal metformin protect the developing fetal brain? Am J Obstet Gynecol. 2025. PMID: 41130438. doi:10.1016/j.ajog.2025.10.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。